The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026
Avacta Group plc (AIM: AVCT) Year-end trading update
Avacta Group plc reported strong operational progress in 2025, having raised £22.5m in equity to support its research and development programmes. The company ended the year with unaudited cash reserves
Avacta (AIM: AVCT) sees strong sentiment recovery in second half of 2025
Avacta (AIM: AVCT) has enjoyed a strong recovery in sentiment during the second half of 2025, with the share price rising from around 30 pence in early July to 58.00 pence
Avacta Therapeutics (AIM: AVCT) reports new AVA6103 pharmacology data
Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days
Early trial success for Avacta (AIM: AVCT) as AVA6000 shows meaningful tumor responses
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society
Avacta Therapeutics (AIM: AVCT) Preliminary Data in Faridoxorubicin Phase 1b Trial
Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort
Welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub!
Welcome to the Avetix Group YouTube channel.
Avacta Therapeutics (AIM: AVCT) Presents preclinical data at AACR-NCI-EORTC
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
Avacta Impresses at ESMO with Positive Phase 1a Data for pre|CISION® Platform
Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION® platform at the European Society of Medical Oncology Annual Congress
Avacta Unveils Data on First Dual-Payload Peptide Drug Conjugate at International Cancer Conference
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
Avacta’s pre|CISION® Platform Shortlisted for AIM Technology of the Year
Avacta Group plc has announced that its proprietary pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award.
Avacta Secures £3.25m Through Oversubscribed Placing and Amends Convertible Bond
Avacta Group PLC has announced a successful conditional equity fundraise, raising gross proceeds of £3.25 million through an oversubscribed placing. The placing comprised 6,500,000 new ordinary shares issued at 50